Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript
Thursday, July 30, 2026, at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Josh Brodsky Chief Executive Officer - Yvonne Greenstreet Chief Financial Officer - Jeff Poulton Chief Commercial Officer - Tolga Tanguler Chief Research and Development Officer - Pushkal Garg TAKEAWAYS Total Net Product Revenues -- $1.2 billion, representing 74% growth versus the second quarter of last year driven by the uptake of AMVUTTRA in ATTR cardiomyopathy.
How this was made
The 30-second read
Why it matters
The most decision-relevant items are the revised 2026 revenue guidance ranges, the explanation that second-line demand normalized after earlier pent-up demand, and the continued strength in AMVUTTRA uptake (including a first-line initiation mix shift).
Market read
Traders can update expectations for 2026 revenue trajectory using the disclosed guidance revisions and the demand-normalization rationale, while also monitoring whether first-line penetration offsets the second-line slowdown.
What to watch
Inventory dynamics (US TTR offset) and modeled efficacy assumptions for nucresiran may be less certain than reported revenues, so investors may over-extrapolate from run-rate and modeled thresholds.
Background
Alnylam’s Q2 2026 call centers on the ATTR cardiomyopathy franchise (AMVUTTRA and TTR revenues) and the nucresiran TRITON-CM Phase III program, alongside competitive and generic-entry timing.
Ticker impact
Alnylam reported Q2 2026 results and cut full-year product revenue guidance to $4.7B-$5.1B due to normalized second-line demand.
Near-term volatility likely as investors weigh the guidance reduction against AMVUTTRA run-rate and first-line shift.
The article discloses multiple forward-looking numbers (product guidance down, TTR guidance revised, collaboration/royalty up) plus a clear demand normalization explanation from management, which can drive re-rating and positioning into the next earnings window.
Market effects
Reinforces competitive dynamics in ATTR cardiomyopathy between RNAi (AMVUTTRA/nucresiran) and antisense competitors, with generic timing affecting long-duration revenue expectations.
International TTR revenue growth and pricing headwinds are highlighted, suggesting continued geographic mix effects on future margins.
ATTR franchise narrative and competitive trial outcomes can influence sentiment across rare-disease RNAi/ASO peers and partner ecosystems (Roche/Novartis).
Counterpoint
The guidance cut may reflect temporary demand normalization rather than durable share loss, while the first-line shift could extend the runway beyond what the midpoint implies.
Key entities
- companyAlnylam Pharmaceuticals
Reported Q2 2026 results and revised 2026 guidance for TTR franchise, collaboration/royalty revenue, and nucresiran TRITON-CM enrollment/outcomes.
- productAMVUTTRA
ATTR cardiomyopathy therapy whose uptake drove Q2 growth and a stated >$4B annual run rate.
- product_candidatenucresiran
TRITON-CM Phase III program; management cited modeled TTR knockdown and enrollment expansion.
- partnerRoche
Cited as contributing to higher cost reimbursement and collaboration-related guidance.
- partnerNovartis
Cited for higher Leqvio sales by Novartis driving royalty revenue growth.
